BeOne Medicines Ltd. (ONC) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 12 Buy, 1 Hold.
The consensus price target is $409.67 (low: $394.00, high: $425.00), representing an upside of 32.2% from the current price $310.00.
Analysts estimate Earnings Per Share (EPS) of $-5.40 and revenue of $3.72B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-6.12 vs est $-5.40 (missed -13.4%). 2025: actual $34.19 vs est $3.01 (beat +1037.2%). Analyst accuracy: 48%.
ONC Stock — 12-Month Price Forecast
$409.67
▲ +32.15% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for BeOne Medicines Ltd., the average price target is $409.67, with a high forecast of $425.00, and a low forecast of $394.00.
The average price target represents a +32.15% change from the last price of $310.00.
Highest Price Target
$425.00
Average Price Target
$409.67
Lowest Price Target
$394.00
ONC Analyst Ratings
Buy
Based on 13 analysts giving stock ratings to BeOne Medicines Ltd. in the past 3 months
EPS Estimates — ONC
48%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$6.12
vs Est –$5.40
▼ 11.8% off
2025
Actual $34.19
vs Est $3.01
▲ 91.2% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — ONC
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $3.810B
vs Est $3.716B
▲ 2.5% off
2025
Actual $5.343B
vs Est $5.302B
▲ 0.8% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
